Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06940648

Virtuoso Improving Anatomic Bladder Lesion Excision (VIABLE) Trial

A robotic assisted surgery for bladder lesion excision.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital, Chinese University of Hong Kong

Hong Kong

About this study

This is a single-center, non-randomized study to evaluate the use of the Virtuoso Endoscopy System (VES) to perform safe and effective bladder lesion excisions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is 22 years or older.
  • The subject is eligible and fit for transurethral bladder lesion removal and/or biopsy and has an appropriate indication to go through this surgery.
  • The subject is willing and able to provide written informed consent and comply with the study protocol.
  • The subject can undergo general anesthesia per anesthesiologist assessment.
  • The subject's planned aggregated bladder lesion(s) excision specimens are smaller than 3 cm.

Exclusion criteria

  • The subject has acute untreated urinary tract infection or urosepsis.
  • The subject has a documented nickel allergy or nickel sensitivity.
  • The subject is confirmed to be or suspected to be pregnant.
  • The subject is receiving anticoagulants and is unable or not willing to cease the medication for the investigational procedure.
  • The subject belongs to a vulnerable group (prisoner, etc.)
  • The subject has a urethral abnormality, implant, or previous surgery which would conflict with the procedure.
  • The subject has undergone a transurethral bladder resection procedure in the past 6 months.
  • The subject has a history of radiation treatment within the pelvis.
  • Bladder tumor base maximal dimension is greater than 3 cm.
  • Bladder tumor detected during intravesical therapy.
  • Previous histological diagnosis different than non-muscle invasive bladder cancer.
  • Presence or prior history of upper urinary tract malignancy.
  • Eastern Cooperative Oncology Group performance status greater than or equal to 3.
  • American Society of Anesthesiologists physical status classification of IV or above.
  • History of bleeding disorder, coagulation abnormality, or use of anticoagulants.
  • The presence of other active malignancy.
  • Life expectancy <1 yr.

Treatment and study plan

The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.

Device

This study is to evaluate the use of the Virtuoso Endoscopy System (VES), which is a robotic enhanced system, to perform safe and effective bladder lesion excisions.

Primary outcomes

  1. Detrusor muscle presence in the pathologic specimen after VES procedure

    Time frame: Through study completion, an average of 30 days

  2. Adverse events

    Time frame: Intraoperative

  3. Adverse events

    Time frame: Through study completion, an average of 30 days

Secondary outcomes

  1. Rate of conversion to standard cTURBT equipment

    Time frame: Intraoperative

  2. Rate of en bloc excision with VES

    Time frame: Intraoperative

  3. Complications (Clavien-Dindo)

    Time frame: Intraoperative

  4. Significant bladder perforation requiring intervention

    Time frame: Intraoperative

  5. Urethral injury

    Time frame: Intraoperative

  6. Transfusion rate

    Time frame: Intraoperative

  7. Estimated blood loss

    Time frame: Intraoperative

  8. Rate of patients where the obturator nerve complex was observed

    Time frame: Intraoperative

  9. Mortality

    Time frame: Intraoperative

  10. VES surgery procedural time

    Time frame: Intraoperative

  11. Presence of clear, evaluable margins in excised specimen

    Time frame: Through study completion, an average of 30 days

  12. Time of catheterization

    Time frame: Through study completion, an average of 30 days

  13. Time of hospital stay

    Time frame: Through study completion, an average of 30 days

  14. Complications (Clavien-Dindo)

    Time frame: Through study completion, an average of 30 days

  15. Significant bladder perforation requiring intervention

    Time frame: Through study completion, an average of 30 days

  16. Urethral injury

    Time frame: Through study completion, an average of 30 days

  17. 30-day reoperation rate

    Time frame: Through study completion, an average of 30 days

  18. 30-day hospital readmission rate

    Time frame: Through study completion, an average of 30 days

  19. 30-day mortality

    Time frame: Through study completion, an average of 30 days

Sponsors and collaborators

Lead sponsor

Virtuoso Surgical, Inc.

Industry

Collaborators

  • Chinese University of Hong Kong

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 23, 2025
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.